A Phase Ib/II trial assessing volasertib for rhabdomyosarcoma and other pediatric cancer indications.

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 09 Oct 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Oct 2023 According to an Oncoheroes Biosciences media release, U.S. Food and Drug Administration (FDA) has allowed the Boston-based biotech to begin this clinical trial of Volasertib for pediatric oncology.
02 Oct 2023 According to an Oncoheroes Biosciences media release, company has submitted Investigational New Drug (IND) application to the FDA In August seeking permission to initiate clinical trial.After FDAs thorough review and evaluation, Oncoheroes reported that IND have received the green light from the FDA to move forward.
19 Oct 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com